by In2Pharma | Oct 9, 2025 | News
Belgium As of September 1st, 2025, the Algemene Pharmaceutische Bond (APB – General Pharmaceutical Association in Belgium) has ceased the publication of recommended retail prices (RRP) for products that do not fall under regulated pricing schemes. This decision...
by In2Pharma | Jul 31, 2025 | News
Belgium A new web-based eAF (electronic Application Form) from the Product Lifecycle Management Portal (PLM Portal) has been established for variation applications for non-centrally authorised products. The use of this new web-based eAF is recommended, yet, the...
by In2Pharma | Jul 11, 2025 | News
Belgium The Belgian FAQ on nutrition and health claims has been updated (June 2025 version). Several key questions have been revised or expanded. Notable updates include: Definition of a health claim (Q3): The term now explicitly includes statements that indicate the...
by In2Pharma | Jul 1, 2025 | News
Belgium Starting 1 June 2025, the Federal Agency for Medicines and Health Products (FAMHP) will require companies to use a new contact form for inquiries regarding variations and renewals of marketing authorisations for human medicinal products. This form will replace...
by In2Pharma | Jun 11, 2025 | News
Belgium The FAMHP published a section listing medical devices and in vitro diagnostic medical devices notified under Article 10bis of regulations (EU) 2017/745 and 2017/746, introduced by the regulation (EU) 2024/1860. The list includes medical devices that are...
